Article
Efficacy of Bivalent CEACAM6/4-1BBL Genetic Vaccine Combined with Anti-PD1 Antibody in HCT116 Xenograft Mice
2021-08-04
Abstract excerpt
<h4>Background: </h4> Colorectal cancer (CRC) is the second leading cause of cancer death worldwide. Anti-PD1/PD-L1 drugs are feasible treatment for CRC, and genetic vaccine is a promising immunotherapy for cancers. However, anti-tumor efficacy of genetic vaccines including CEACAM6/4-1BBL genes combined with immunocheckpoint inhibitors on CRC has not been reported. We used human colon cancer cell line (HCT116) to...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 8e3c1378-3aac-5a90-a967-833d21a65d61
- DOI
- 10.21203/rs.3.rs-618292/v1
